CJ HealthCare’s K-Cab Tab., the nation’s 30th novel drug, recorded 1.53 billion won ($1.34 million) outpatient prescription sales in a single month after the market release, raising the expectations of becoming a blockbuster drug.
|CJ HealthCare’s K-Cab, a treatment for the gastroesophageal reflux disease|
According to UBIST data, K-Cab (ingredient: tegoprazan), a treatment for the gastroesophageal reflux disease, sold 1.53 billion won in March.
Seoul National University Hospital first started prescribing K-Cab. The Severance Hospital and Samsung Medical Center are likely to follow suit as the medicine recently passed the hospitals’ drug review committee.
As a potassium-competitive acid blocker (P-CAB), K-Cab overcame the shortcoming of conventional therapies such as proton pump inhibitors (PPI). The medicine obtained approval last year and arrived in the market with insurance benefit on March 1. The price is 1,300 won ($1.14) per tablet.
CJ HealthCare is seeking to expand K-Cab’s indication into treat stomach ulcer and eradicate Helicobacter pylori in the stomach.
An expanded indication could give K-Cab a chance to replace widely-used PPI-class drugs.
<© Korea Biomedical Review, All rights reserved.>